Scott Borgstrom

📢 Introducing one of our many #PanelDiscussions during the 2 day #PDDPSUMMIT at the Hilton Boston Park Plaza Email us at [email protected] to learn more! #DrugDiscovery #Preclinical #Antibodies #DrugDevelopment #AI #ML #MedTech #Biopharma #Pharma #Biotech #SmallMolecules #Biologics #LifeScienes #Medicine #Scientists #LifeScience #LargeMolecules

8

⏳ The countdown is on for Wilson Sonsini’s Inaugural Biotech Summit in Boston, October 9-10! ⌛ HIC's CEO and Principal Regulatory Advisor, Deb Autor, will share insights on FDA hot topics and regulatory trends alongside fellow industry leaders. Why attend? 👥 Connect with influential and knowledgeable leaders at the intersection of biotech, venture capital, and policy. ✍ Learn about regulatory trends, antitrust issues, and strategic collaborations that drive innovation in medical therapies. 🗣 Engage in topics that will highlight ways to leverage AI in healthcare. You don't want to miss this event! #BiotechSummit #FDA #Biotech #Boston #WilsonSonsini #Innovation #MedTech #PharmaBiotech #Regulatory

6

Yesterday, Gordon Haner, MBA, LATG, ILAM was onsite at EMD Serono, Inc. for a Biotech Vendor Services, Inc. vendor show! Thank you to all those who came to talk to Gordon about GemPharmatech's mouse models and preclinical services. If you are in the #bostonbiotech community make sure to reach our to Gordon if you do preclinical research with mouse models. Also a thank you to Matthew Potter and BVS! See you again soon, new EMD and MilliporeSigma friends! #preclinicalresearch #oncology #autoimmune #vendorshow #bvs #bvsvendorshow

29

BIG NEWS! Genezen has signed an agreement to acquire uniQure’s commercial gene therapy manufacturing operations in Lexington, Massachusetts. This strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. Steve Favaloro, President and Chief Executive Officer of Genezen, commented, “...This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions. We are honored to deliver these services to our current customers and the patients they serve, and are well positioned to immediately extend our support to even more customers in Lexington.” #cdmo #viralvectors #cellandgenetherapy #celltherapy #genetherapy #precisionmedicine #mergersandacquisitions #investment #finance #pharma #biotech CSL Ampersand Capital Partners https://lnkd.in/eqDDc_cf

194

15 Comments

It's under a week until US Pharma and Biotech Summit! Greg Dombal, President of DLRC Inc., will be attending this year's event. With over 25 years of experience in pharmaceuticals, biotechnology, medical technology, and consulting, this is the perfect opportunity to connect with Greg and discuss how DLRC can support your regulatory goals. To request a meeting, search for DLRC in the partnering app or email our team at [email protected]. See you there! #Pharma #PharmaEvents #Biotech #RegulatoryAffairs

27

Missed Genedata at the #ASCGT conference? No worries! There's still time to download our most talked-about poster from the conference, all about the latest developments in #GeneTherapy analytical development, specifically #NGS-based #CQA monitoring for #gene therapies. 👉 Download today: https://buff.ly/44MpTcv #DigitalizingBiopharma #GenedataSelector #bioinformatics #qualitycontrol

20

Innovation starts here. For sponsors looking to make a real impact, #GeneTherapies are promising. Pharmacokinetic analysis can shape dosing strategies and provide input into drug safety & efficacy – learn more: https://bit.ly/3zDqPRs #CGT #GeneTherapy #PKassessments

17

PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™ WARREN, N.J., May 14, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024. "We are excited to be one step closer to bringing an approved therapy to patients with AADC deficiency in the United States," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. "The data collected to date continue to support the transformative benefit of Upstaza, this highly innovative gene therapy directly infused into the brain." About Upstaza™ (eladocagene exuparvovec) Upstaza is a one-time gene replacement therapy indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L–amino acid decarboxylase (AADC) deficiency with a severe phenotype. It is a recombinant adeno-associated virus serotype 2 (AAV2) https://lnkd.in/e5EvQp7D

31

Are you involved in biologics or biosimilar patent litigation?   The Pharma & Biotech Patent Litigation event series is coming to Philadelphia this October 29-30 with an audience of 150  industry leaders including the likes of Sandoz, USPTO, Regeneron, Alvotech, Kite Pharma, Sanofi, Univercells, CAFC and more. Together we’ll address the latest case law and updates shaping the U.S. life science litigation strategy. Join Petra Scamborova, Raymond Parker III, JD, PhD, Sesha Kumar and Eric Choi during one of our key panel sessions focused on biologics and biosimilar litigation in the U.S. market exploring the latest global legal challenges and uncertainties surrounding biologics, BPCIA, and regulatory exclusivity litigation. Gain critical insights into effective litigation strategies that can keep you ahead in this rapidly evolving field. Discover all the sessions today right here: https://lnkd.in/eJsz3FeZ #patentlitigation #IPGLOBAL #inhouse #biologics #biosimilar

5